[Promoting effect of estrogen and basic fibroblast growth factor on proliferation of hemangioma vascular endothelial cell in vitro].
OBJECTIVE
To observe the influences of estradiol (E2), basic fibroblast growth factor (bFGF), and tamoxifen (TAM) on the proliferation of hemangioma vascular endothelial cell (HVEC).


METHODS
Two strawberry hemangioma from 2 infants (case 1 and case 2) were prepared for HVEC culture. The HVEC on passage 3 were cultured in estrogen-free improved minimum essential medium (IMEM) and subjected to various treatments with 100 pg/ml 17-beta-E2, 10 ng/ml bFGF, and 1 x 10(-6) mol/L 4-OH-tamoxifen (4-OH-TAM). The experiment was divided into 5 groups: group 1 (IMEM, control group), group 2(17-beta-E2), group 3(bFGF), group 4(17-beta-E2/bGFG) and group 5(17-beta-E2/ bGFG/4-OH-TAM). The cell count (CC) and DNA proliferation index (PI) were determined.


RESULTS
Two cases of HVEC were successfully cultured in vitro. The HVEC showed cobblestones-like under microscopy and factor VIII-related antigen(also named as von Willebrand factor, vWF) was positive by immunochemical staining. At 9 days in case 1: CC and PI remained unchanged in the control group; CC and PI were slightly increased in group 2, being 1.4 and 1.6 times as much as those in the control group respectively (P<0.05); CC and PI significantly increased in group 3, being 2.6 and 2.3 times as much as those in the control group respectively (P<0.01); CC and PI increased remarkably in group 4, being 3.7 and 2.9 times as much as those in the control group respectively (P<0.01); CC and PI were down to the levels of controls in group 5(P>0.05). The results in case 2 were similar to those in case 1.


CONCLUSIONS
In vitro, the promoting effect of bFGF on HVEC proliferation is much stronger than that of estrogen. Estrogen and bFGF enhance this proliferation in a synergistic manner, which can be inhibited by tamoxifen.
Liu
Jiangbin
J
Department of Surgery, Children's Hospital of Fudan University, Shanghai, 200032, P. R. China. ljbin888@yahoo.com.cn
Xiao
Xianmin
X
Sheng
Minli
M
D002452:Cell Count; D002453:Cell Cycle; D049109:Cell Proliferation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006391:Hemangioma / Q000473:pathology*; D006801:Humans; D008297:Male; D012878:Skin Neoplasms / Q000473:pathology*; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D013629:Tamoxifen; D016222:Fibroblast Growth Factor 2; D004958:Estradiol